Xu, Christine L.
Adu-Brimpong, Joel
Moshfeghi, Henry P.
Rosenblatt, Tatiana R.
Yu, Michael D.
Ji, Marco H.
Wang, Sean K.
Zaidi, Moosa
Ghoraba, Hashem
Michalak, Suzanne
Callaway, Natalia F.
Kumm, Jochen
Nudleman, Eric
Wood, Edward H.
Patel, Nimesh A.
Stahl, Andreas
Lepore, Domenico
Moshfeghi, Darius M.
Funding for this research was provided by:
Research to Prevent Blindness (P30-EY026877)
Article History
Received: 18 December 2022
Accepted: 6 September 2023
First Online: 14 September 2023
Competing interests
: HPM–Eugster Endowed Student Research and Internship Fund, AS—Bayer (research grant, honoraria), Novartis (research grant, honoraria), Roche (honoraria), Alcon (consultant fees), DMM–Affamed (C), Ainsly Limited (C,E), Akebia (C), Alexion (C), Apellis (PI), dSentz, Inc. (F,E,BOD), Feliqs (C), Genentech (G), Icon (C, DSMB), Plenoptika Inc. (C,E), Pr3vent Inc (F,E,BOD), Prime Medical Education (C), Promisight, Inc (F,E,BOD), Pykus (E,SAB), Regeneron (SC,PI), SLACK, Inc (C), University of Miami (H), Vanotech Chengdu (C), Vindico (C), Visunex Medical Systems Co., Ltd (E), RESEARCH TO PREVENT BLINDNESS, INC., NEI P30-EY026877 NFC- Genentech (C,E,S) CLX, JA, TRR, MDY, MHJ, SKW, MZ, HG, SM, JK, EN, EHW, NAP, DL declare no competing interests.